University of Arizona Launches $12 Million Rapamycin Clinical Trial

Key Takeaways

• $12M philanthropic funding enables first investigator‑led rapamycin trial
• Phase 3 study targets adults 65+ with two‑year treatment
• Primary endpoints: frailty progression and IL‑6 inflammation reduction
• Positive results could fast‑track FDA approval for anti‑aging drug

Pulse Analysis

Rapamycin, originally approved to prevent organ‑transplant rejection, has emerged as a leading candidate in the quest to extend human healthspan. By inhibiting the mechanistic target of rapamycin (mTOR) pathway, the drug mimics caloric‑restriction signals that promote cellular repair, autophagy, and metabolic efficiency. A growing body of pre‑clinical and early‑phase human studies shows that low‑dose rapamycin can boost vaccine responses, improve oral health, and reduce markers of chronic inflammation in older adults. These findings have sparked intense interest among geroscientists, positioning rapamycin at the forefront of translational aging research.

The University of Arizona’s R. Ken Coit College of Pharmacy is now translating that promise into a rigorously designed Phase 3 trial, the first investigator‑led study of its kind in the United States. Funded by a $12 million philanthropic gift from alumnus R. Ken Coit, the double‑blind, randomized protocol will enroll participants aged 65 and older, administering low‑dose rapamycin or placebo for two years with a third year of follow‑up. Researchers will assess two primary outcomes: the rate of transition to frailty and circulating interleukin‑6 levels, a key inflammatory biomarker linked to age‑related morbidity.

If the trial demonstrates that rapamycin safely improves physical function and lowers IL‑6, it could accelerate FDA approval for an anti‑aging indication, opening a multi‑billion‑dollar market for longevity therapeutics. Beyond commercial potential, the study would provide a template for how private philanthropy can de‑risk high‑impact biomedical projects that might otherwise struggle for federal grant support. Successful results would also inform ancillary investigations into related pathways, encouraging broader adoption of mTOR modulation in preventive medicine. Ultimately, the trial could shift the paradigm from treating age‑related diseases to preserving resilience throughout the later years of life.